Oncology News | pharmaphorum

News

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.

News

Enhertu gets first okay for HER2-ultralow breast cancer

Enhertu gets much-anticipated new FDA approval in breast cancer that expands its label and makes it an earlier option in the treatment pathway.

News

Italian decision sets up launch of Oncopeptides' Pepaxti

Oncopeptides hopes to reignite growth in multiple myeloma drug Pepaxti after getting reimbursement approval in Italy.

News

Martin Olin has been named chief executive of the UK start-up

UK biotech Swarm lands with a T-cell therapy mission

UK firm Swarm Oncology launches with a T-cell therapy platform to treat solid tumours, with a Resolution Therapeutics co-founder in the pilot seat.

News

Ascentage raises $126m in first biotech IPO of 2025

China's Ascentage completes the first US biotech IPO of 2025, raising $126m for its pipeline of small-molecule cancer drugs.

News

GSK backs £50m Oxford University cancer vaccine programme

A GSK alliance with Oxford University aims to identify precancerous changes in cells that could form the basis of preventive vaccines.

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Enhertu gets first okay for HER2-ultralow breast cancer

Italian decision sets up launch of Oncopeptides' Pepaxti

UK biotech Swarm lands with a T-cell therapy mission

Ascentage raises $126m in first biotech IPO of 2025

GSK backs £50m Oxford University cancer vaccine programme

Allergy Tx plots grass pollen jab launch after German okay

The AI imperative: Establishing the standard for modern clin...

News

Editor's Picks